This article is more than 5 years old. Information may no longer be current.
University of Michigan Comprehensive Cancer Center appoints director
Click Here to Manage Email Alerts
Eric Fearon, MD, PhD, has been named director of the University of Michigan Comprehensive Cancer Center.
Fearon, a professor of oncology at the university, is recognized for his research related to cancer genetics. He is credited for improving the understanding of gene defects that contribute to the development and spread of colon and rectal cancers.
Fearon succeeds Theodore Lawrence, MD, PhD. Lawrence remains chair of the university’s department of radiation oncology.
“Our cancer center has a history of success, with many exciting recent and ongoing initiatives,” Fearon said in a press release. “I am honored to have the opportunity to continue moving us forward.
“We are in the enviable position of having a tremendous culture of collaboration, innovation and teamwork,” he added. “Our faculty, staff and trainees are committed to the highest quality, patient-centered care, with an emphasis on integrity, safety, service, compassion and respect.”
Fearon has been with the university since 1995. He previously served as associate director for basic science research at the cancer center, and he assumed the role of deputy director in 2005. He also served as division chief for molecular medicine and genetics within the department of internal medicine.
“Dr. Fearon has been intimately involved in many of the cancer center’s strategic initiatives over the past two decades,” Marschall Runge, MD, PhD, executive vice president of medical affairs at University of Michigan and dean of its medical school, said in the press release. “Based on this experience and his many collaborative efforts and partnership with the outstanding faculty, staff and trainees in the cancer center, I’m confident Dr. Fearon will build on our cancer program’s excellent reputation. We will continue to advance the understanding of cancer’s origins and behavior, and translate that knowledge to improve treatment, survival and quality of life for patients and families facing cancer.”